Abstract
Portal vein thrombosis (PVT) dramatically changes the prognosis of cirrhotic patients, especially those waiting for liver transplantation. However, the possible contribution to PVT of von Willebrand factor (VWF) and ADAMTS-13 is poorly documented. The aim of our study was to assess the presence of alterations of VWF and ADAMTS-13 serum levels in cirrhotic patients with PVT. Twenty-four patients with PVT (group PVT) and 60 without PVT (group without PVT) were enrolled. A comprehensive analysis of biochemical and hemostatic parameters was performed. ADAMTS-13 activity was significantly lower in group A (median 16.8 vs. 69.1 %, p = 0.0047). Group PVT, compared to group without PVT, showed a significantly higher VWF:act, (median 308.4 vs 203.3 %, p = 0.032), whereas no difference was observed for VWF:Ag, FVIII level and the presence of risk factors for venous thromboembolism. No correlation was found between the Child–Pugh score and ADAMTS-13 activity. In multivariable logistic regression analysis performed on data concerning both group PVT and without PVT, only the ADAMTS-13 activity (p = 0.007) was independently and inversely associated with PVT. In conclusion, ADAMTS-13 activity is independently associated with PVT in cirrhotic patients.
Similar content being viewed by others
Abbreviations
- PVT:
-
Portal vein thrombosis
- VWF:
-
von Willebrand factor
- ADAMTS-13:
-
A disintegrin and metalloprotease with thrombospondin 1 repeats Nr. 13
- VTE:
-
Venous thromboembolism
- VWF:act:
-
VWF activity
- VWF:Ag:
-
VWF antigen
- UL-VWF:
-
Ultralarge VWF
- PT:
-
Prothrombin time
- APTT:
-
Activated partial thromboplastin time
References
Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD (1986) Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 78(6):1456–1461
George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371(7):654–666
George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB (2004) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 44(2):294–304
Di Stasio E, Lancellotti S, Peyvandi F, Palla R, Mannucci PM, De Cristofaro R (2008) Mechanistic studies on ADAMTS13 catalysis. Biophys J 95(5):2450–2461
Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C (2001) A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 130(4):475–480
Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, Fujimura Y (2005) Localization of ADAMTS13 to the stellate cells of human liver. Blood 106(3):922–924
Turner NA, Nolasco L, Ruggeri ZM, Moake JL (2009) Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 114(24):5102–5111
Suzuki M, Murata M, Matsubara Y, Uchida T, Ishihara H, Shibano T, Ashida S, Soejima K, Okada Y, Ikeda Y (2004) Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 313(1):212–216
Manea M, Kristoffersson A, Schneppenheim R, Saleem MA, Mathieson PW, Morgelin M, Bjork P, Holmberg L, Karpman D (2007) Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 138(5):651–662
Lancellotti S, De Cristofaro R (2011) Structure and proteolytic properties of ADAMTS13, a metalloprotease involved in the pathogenesis of thrombotic microangiopathies. Prog Mol Biol Transl Sci 99:105–144
Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y (2006) Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107(2):528–534
Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM (2003) Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 88(9):1029–1034
Reiter RA, Varadi K, Turecek PL, Jilma B, Knobl P (2005) Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 93(3):554–558
Claus RA, Bockmeyer CL, Sossdorf M, Losche W (2010) The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure? Curr Mol Med 10(2):236–248
Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98(9):2730–2735
Niiya M, Uemura M, Zheng XW, Pollak ES, Dockal M, Scheiflinger F, Wells RG, Zheng XL (2006) Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost 4(5):1063–1070
Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, Isonishi A, Ishikawa M, Yagita M, Morioka C, Yoshiji H, Tsujimoto T, Kurumatani N, Fukui H (2008) Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 99(6):1019–1029
Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW (2006) Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 44(1):53–61
Takaya H, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, Morioka C, Ishizashi H, Hori Y, Fujimoto M, Tsujimoto T, Kawaratani H, Toyohara M, Kurumatani N, Fukui H (2012) ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child–Turcotte–Pugh score and the Model for End-Stage Liver Disease score. Hepatol Res 42(5):459–472
Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL (2008) Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 6(7):1233–1235
Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF (2004) Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104(1):100–106
Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F (1996) High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 23(6):1377–1383
Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, Payer BA, Trauner M, Peck-Radosavljevic M, Ferlitsch A (2012) von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 56(4):1439–1447
Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F (2005) Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 54(5):691–697
Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR (2000) Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd–Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 96(7):2364–2368
Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, Dell’era A, Pappalardo E, Mannucci PM (2005) Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 41(3):603–608
Parikh S, Shah R, Kapoor P (2010) Portal vein thrombosis. Am J Med 123(2):111–119
D’Amico M, Pasta F, Pasta L (2015) Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population. Gene
Amitrano L, Guardascione MA, Ames PR, Margaglione M, Iannaccone L, Brancaccio V, Balzano A (2006) Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. Thromb Haemost 95(2):221–223
Zoller B, Li X, Sundquist J, Sundquist K (2010) Familial risks of unusual forms of venous thrombosis: a nationwide epidemiological study in Sweden. J Intern Med 270(2):158–165
Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R, Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, Landolfi R, Gasbarrini A (2009) Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 51(4):682–689
Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora A, Di Maurizio L, Bombardieri G, De Cristofaro R, De Gaetano AM, Landolfi R, Gasbarrini A (2010) Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol 16(2):143–155
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649
Yerdel MA, Gunson B, Mirza D, Karayalcin K, Olliff S, Buckels J, Mayer D, McMaster P, Pirenne J (2000) Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 69(9):1873–1881
de Maistre E, Volot F, Mourey G, Aho LS, Ternisien C, Briquel ME, Bertrand MA, Tardy B, Frotscher B, Nguyen P, Dumont L, Vandroux D, Hezard N, Trossaert M (2014) Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance. Thromb Haemost 112(4):825–830
Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F (2014) A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 20(1):147–153
Lancellotti S, Dragani A, Ranalli P, Petrucci G, Basso M, Tartaglione R, Rocca B, De Cristofaro R (2016) Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost 13(7):1226–1237
Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129(1):93–100
Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B, Rutella S, Pitocco D, Mannucci PM, De Cristofaro R (2010) Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: a new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 48(3):446–456
Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA (2007) Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 5(4):866–867
Lancellotti S, Dragani A, Ranalli P, Petrucci G, Basso M, Tartaglione R, Rocca B, De Cristofaro R (2015) Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost
Toh CH, Hoots WK (2007) The scoring system of the scientific and standardisation committee on disseminated intravascular coagulation of the international society on thrombosis and haemostasis: a 5-year overview. J Thromb Haemost 5(3):604–606
Jamieson NV (2000) Changing perspectives in portal vein thrombosis and liver transplantation. Transplantation 69(9):1772–1774
Amitrano L, Guardascione MA, Ames PR (2007) Coagulation abnormalities in cirrhotic patients with portal vein thrombosis. Clin Lab 53(9–12):583–589
Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T (2013) An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 58(2):752–761
Wiese S, Timm A, Nielsen LB, Goetze JP, Bendtsen F, Moller S (2016) Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis. Dig Liver Dis 48(4):404–408
Taniguchi S, Hashiguchi T, Ono T, Takenouchi K, Nakayama K, Kawano T, Kato K, Matsushita R, Nagatomo M, Nakamura S, Nakashima T, Maruyama I (2010) Association between reduced ADAMTS13 and diabetic nephropathy. Thromb Res 125(6):e310–e316
Tati R, Kristoffersson AC, Stahl AL, Morgelin M, Motto D, Satchell S, Mathieson P, Manea-Hedstrom M, Karpman D (2011) Phenotypic expression of ADAMTS13 in glomerular endothelial cells. PLoS One 6(6):e21587
DeLeve LD (2015) Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology 61(5):1740–1746
Calvaruso V, Maimone S, Gatt A, Tuddenham E, Thursz M, Pinzani M, Burroughs AK (2008) Coagulation and fibrosis in chronic liver disease. Gut 57(12):1722–1727
Acknowledgments
RDC gratefully acknowledges financial support from the Ministry of University and Research of Italy (MIUR-Linea D1 2013–2014). No writing support was provided.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
The procedures and the experiments performed in this investigation respected the ethical standards in the Helsinki Declaration of 1975, as revised in 2000 and 2008, as well as the Ethical Committee regulations of the Catholic University of the Sacred Heart.
Informed consent
Patients admitted at the “Fondazione Policlinico Universitario Agostino Gemelli” received systematic information about the use of de-identified anonymous data for the purpose of retrospective studies.
Additional information
Maurizio Pompili is the senior coauthor.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lancellotti, S., Basso, M., Veca, V. et al. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Intern Emerg Med 11, 959–967 (2016). https://doi.org/10.1007/s11739-016-1467-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-016-1467-x